Sign in
Taking people in FrancePhase 2

Metformin compared with placebo for high pressure in liver veins in cirrhosis

Tests metformin against placebo in people with cirrhosis and portal hypertension taking carvedilol.

Key facts

Who runs it
Assistance Publique Hopitaux De Paris
Where
Bobigny, Clichy, Créteil, Creteil Cedex, Paris, St Denis Cedex, Suresnes, and Villejuif, FranceSee the 8 sites
Registry title
Portal hypertension in cirrhosis
Status
Recruiting
Phase
Phase 2
People taking part
76 people, planned
Started
4 Mar 2025
Planned end
1 Sept 2026
Type of study
Interventional
Record updated
7 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cirrhosis and high blood pressure in the liver's veins (portal hypertension) who already take carvedilol. It compares metformin with a placebo (dummy pill) for 28 days.

Age
18 years and older
Sex
All sexes
Disease stage
Cirrhosis, Child-Pugh A or B. The doctor judges it likely that the HVPG (pressure gradient in the liver veins) is ≥ 12 mm Hg. The cause of cirrhosis is active, or was resolved at least 6 months ago.
Earlier treatment
Must take carvedilol (≥ 6,25 mg/day) at a stable dose for at least one month.
Biomarker or test result
Likely HVPG ≥ 12 mm Hg.

Main reasons for not taking part

  • Liver cancer with a nodule > 3 cm (1.2 in) or more than 3 nodules on scans in the past 6 months
  • Serum total bilirubin > 50 µmol/L
  • Prothrombin ratio < 50 %
  • Transaminases (liver enzymes) > 5 times the upper normal limit
  • Needed fluid drained from the belly (paracentesis) at least once in the last 6 months

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Absence of hepatocellular carcinoma outside at least one nodule > 3 cm in diameter, or more than 3 nodules, on ultrasound, CT-scan or MRI performed during the previous 6 months
  • Written informed consent to participate in the study
  • Medical insurance coverage
  • For child-bearing aged women, contraception using oestroprogestative, progestative, intrauterine device, or mechanical contraception
  • Diagnosis of cirrhosis based on a liver biopsy, or on clinical, biological, endoscopic, and radiological evidence
  • Active cause of cirrhosis, or resolution (alcohol cessation, sustained virological response to direct-acting antiviral treatment for HCV, initiation of nucleoside/nucleotide analog treatment for HBV) for at least 6 months
  • Child-Pugh A or B
  • High likelihood of HVPG ≥ 12 mm Hg based on investigator’s judgement, _confer criteria in the protocole
  • Treatment with carvedilol (≥ 6,25 mg/day) at a stable dose for at least one month

Who cannot take part

  • Serum total bilirubin > 50 µmol/L
  • Transaminases > 5 ULN
  • Prothrombin ratio < 50 %
  • Need for at least one paracentesis for ascites fluid evacuation in the last 6 months

Where in France

  • Assistance Publique Hopitaux De ParisBobigny, FranceTaking people
  • Assistance Publique Hopitaux De ParisClichy, FranceTaking people
  • Centre Hospitalier Intercommunal CréteilCréteil, FranceTaking people
  • Assistance Publique Hopitaux De ParisCreteil Cedex, FranceTaking people
  • Assistance Publique Hopitaux de ParisParis, FranceTaking people
  • Centre Hospitalier General De St DenisSt Denis Cedex, FranceTaking people
  • Hospital FochSuresnes, FranceTaking people
  • Assistance Publique Hopitaux De ParisVillejuif, FranceTaking people

About the trial

What the trial wants to find out

To evaluate the effect of metformin versus placebo during 28 days on HVPG, in patients with cirrhosis and a HVPG ≥ 12 mm Hg already treated with carvedilol. Objectif of the ancillary study : To study the effect of metformin on postprandial changes in systemic haemodynamics and HVPG.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Effects of Metformin on hepatic venous pressure gradient in patients with cirrhosis and portal hypertension – A randomized placebo-controlled study
Plain-language title
Metformin compared with placebo for high pressure in liver veins in cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
7 September 2026